The Upstate Carolina Community Clinical Oncology Program (UC-CCOP) has achieved a national reputation for excellence in community cancer care through its 28-year participation in programs of the National Cancer Institute. The UC-CCOP is one of 27 CCOPs that have been continuously funded since 1983. The UC-CCOP seeks to meet the community's need for novel and relevant studies of promising therapeutic and treatment modalities and cancer control and prevention research. The ongoing mission of the UC-CCOP is to assure that every person in the region served is provided an opportunity for participation in a national cancer prevention and/or treatment clinical trial. UC-CCOP strives to provide education about cancer and all NCI clinical trials programs. This grant application encompasses and defines clear objectives of an ever-expanding vision for the UC-CCOP. Goals for this grant cycle: ?Increase patient accrual to cancer treatment, prevention and control clinicl trials sponsored by the NCI and CCOP research bases. ?Increase the number of clinical trial participants from underrepresented populations through continued collaboration with the NCI and proposed strategic initiatives. ?Increase the portfolio of biospecimen/translational clinical trials in collaboration and partnership with participating research bases and the NCI. ?Expand availability of survivorship clinical trials. ?Maintain high-quality data management. ?Improve early phase trial participation through infrastructure and process development. Key strategies to achieving the above goals include (1) expanding the "multidisciplinary approach" to foster the UC-CCOP and Gibbs Cancer Center patient navigator program in order to determine the patient navigator's potential role in and beneficial effects on clinical trial accrual and successful completion of clinical trials, (2) partnering with the NCI to be a pilot site to grow translational research in the community, and (3) utilizing our Minority and Outreach Navigators to strengthen and further develop partnerships with community organizations.

Public Health Relevance

The UC-CCOP continues to provide the community access to the most up-to-date clinical trials available through the NCI. This partnership allows us the opportunity to expand clinical trial accrual in a community-based setting, in turn providing state-of-the-art treatment regardless of race, gender, ethnicity or age.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035119-29
Application #
8511573
Study Section
Special Emphasis Panel (ZCA1-SRLB-E (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1983-09-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
29
Fiscal Year
2013
Total Cost
$1,065,000
Indirect Cost
$229,017
Name
Spartanburg Regional Medical Center
Department
Type
DUNS #
052072048
City
Spartanburg
State
SC
Country
United States
Zip Code
29303
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62

Showing the most recent 10 out of 195 publications